ClinicalTrials.gg
CompletedNCT07622433Updated Sep 28, 2026

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

A Phase 1 interventional study of Laroprovstat/ezetimibe FCDP and Laroprovstat STP in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Updated Sep 28, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hyperlipidemias by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hyperlipidemias · AstraZeneca.

Enrollment
10th of 11
18 · median 334
Started
2026
with 1 other
Phase 1
2 of 20
none open now
Registered
20th of 20
by date

Among the 20 studies in Hyperlipidemias by AstraZeneca, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1, and was the 20th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 20 studies in Hyperlipidemias by AstraZeneca is open now. The open studies under Hyperlipidemias, anywhere →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Hyperlipidemias by AstraZeneca as a file.
02

Study summary

The purpose of this study is to assess how well laroprovstat and ezetimibe combined in a single tablet to be taken by mouth works and what the body does to the drug (pharmacokinetics) compared with laroprovstat and ezetimibe individual tablets to be taken by mouth (relative bioavailability) as well as to see if there is any effect of eating compared to fasting (food effect) in healthy adults.

Read the detailed description

This is a randomized, open-label, 4-period, single-dose, cross-over study.

The study will comprise of a screening period, 4 treatment periods, and 3 washout periods. The following treatments will be given during the study:

  • Treatment A: laroprovstat/ezetimibe fixed combination drug product (FCDP) test formulation in fasted state
  • Treatment B: laroprovstat tablet plus ezetimibe reference formulations in fasted state
  • Treatment C: laroprovstat/ezetimibe FCDP test formulation in fed state
  • Treatment D: laroprovstat/ezetimibe FCDP test formulation-slow variant in fasted state

Participants will be randomly assigned to either of the 3 treatment sequences: ABCD, BCAD, or CABD.

03

Conditions studied

  • Healthy Participants

Keywords

  • Fixed Combination Drug Products
  • Bioavailability
  • Pharmacokinetics
  • Cross-over study
  • Hyperlipidemia
  • Dyslipidemia
  • Relative bioavailability
  • Food effect
  • Oral Formulations
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants aged 18 to 55 years at the time of signing consent.
  • All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.
  • Females of must not be lactating and if heterosexually active must agree to use an approved method of highly effective .
  • Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class to laroprovstat or ezetimibe.
  • Treatment with any lipid lowering therapy or laroprovstat within the 3 months prior to the Screening Visit.
  • Treatment with drugs for reduction or inhibition of Proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit or inclisiran at any time.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment A

    Each participant will receive single dose treatment of laroprovstat/ezetimibe FCDP test formulation in a fasted state.

    Drug: Laroprovstat/ezetimibe FCDP

  • Experimental
    Treatment B

    Each participant will receive single dose treatment of laroprovstat plus ezetimibe single therapy product (STP) reference formulations in a fasted state.

    Drug: Laroprovstat STP · Drug: Ezetimibe STP

  • Experimental
    Treatment C

    Each participant will receive single dose treatment of laroprovstat/ezetimibe FCDP test formulation in a fed state.

    Drug: Laroprovstat/ezetimibe FCDP

  • Experimental
    Treatment D

    Each participant will receive single dose treatment of laroprovstat/ezetimibe FCDP test formulation (slow variant) in a fasted state.

    Drug: Laroprovstat/ezetimibe FCDP-slow variant

Interventions

  • DrugLaroprovstat/ezetimibe FCDP

    Laroprovstat/ezetimibe will be administered orally.

  • DrugLaroprovstat STP

    Laroprovstat will be administered orally.

  • DrugEzetimibe STP

    Ezetimibe will be administered orally.

  • DrugLaroprovstat/ezetimibe FCDP-slow variant

    Laroprovstat/ezetimibe slow variant will be administered orally

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To evaluate the relative bioavailability between the FCDPs and the STPs of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To evaluate the relative bioavailability between the FCDPs and the STPs of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  3. Maximum observed drug concentration (Cmax)

    To evaluate the relative bioavailability between the FCDPs and the STPs of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

Secondary outcomes

  1. Plasma Time to reach maximum observed concentration (tmax)

    To examine the pharmacokinetic (PK) profiles of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe when administered as FCDPs or STPs.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  2. Terminal elimination half-life (t½λz)

    To examine the PK profiles of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe when administered as FCDPs or STPs.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  3. Apparent total body clearance (CL/F)

    To examine the PK profiles of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe when administered as FCDPs or STPs.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  4. Apparent volume of distribution based on the terminal phase (Vz/F)

    To examine the PK profiles of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe when administered as FCDPs or STPs.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  5. AUCinf

    To examine the effect on the PK profiles of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe when administered as an FCDP with a high-fat meal compared to when administered as an FCDP in the fasted state.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  6. AUClast

    To examine the effect on the PK profiles of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe when administered as an FCDP with a high-fat meal compared to when administered as an FCDP in the fasted state.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

  7. Cmax

    To examine the effect on the PK profiles of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe when administered as an FCDP with a high-fat meal compared to when administered as an FCDP in the fasted state.

    Time frame: Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Sep 2026, 2 months.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 2 months is below that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartActual
Jun 10, 2026
Primary completionActual
Sep 6, 2026
CompletionActual
Sep 6, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 28, 2026
Primary completion
Sep 7, 2026→Sep 6, 2026 (actual)
Sep 28, 2026
Study completion
Sep 7, 2026→Sep 6, 2026 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Active, not recruiting→Completed
    Primary completion Sep 7, 2026→Sep 6, 2026 (now actual)
    Study completion Sep 7, 2026→Sep 6, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07622433
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jun 10, 2026
Primary completion
Sep 6, 2026
Completion
Sep 6, 2026
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion